Analysts think ATYR stock price could increase by 416%
Dec 08, 2024, 12:26 PM
18.15%
What does ATYR do
aTyr Pharma, based in San Diego, focuses on developing therapies targeting tRNA synthetase biology for fibrosis and inflammation, with efzofitimod as its lead candidate for interstitial lung disease. The company went public on May 7, 2015, and has 56 employees.
9 analysts think ATYR stock price will increase by 416.07%. The current median analyst target is $17.34 compared to a current stock price of $3.36. The lowest analysts target is $9.09 and the highest analyst target is $36.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
